Ontology highlight
ABSTRACT:
SUBMITTER: Lad DP
PROVIDER: S-EPMC6439022 | biostudies-literature | 2019 Apr
REPOSITORIES: biostudies-literature
Lad Deepesh P DP Malhotra Pankaj P Khadwal Alka A Prakash Gaurav G Jain Arihant A Varma Subhash S
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion 20180908 2
Ibrutinib is the only approved novel agent that is available for the treatment of relapsed-refractory and treatment-naive chronic lymphocytic leukemia patients with deletion 17p or TP53 mutation in India. The cost of ibrutinib is still prohibitive for most Indian CLL patients. We report here for the first time dose reductions due to the patient preference of financial toxicity. We prospectively followed up patients of CLL receiving ibrutinib at a tertiary referral center in India. The period of ...[more]